A dual GIP and GLP-1 receptor agonist developed by Eli Lilly, Tirzepatide, has demonstrated weight loss results up to 22.5% in diabetes and obesity management
Inhibits NF-kB [ 15 ], which is associated with Alzheimers [ 153 ], Parkinsons [ 154 ], ALS [ 155 ], Schizophrenia [ 51 ], Bipolar, and possibly Anorexia [ 156 ]
Mechanisms of Action Insulin Secretion : GLP-1 enhances the secretion of insulin from pancreatic beta cells in a glucose-dependent manner
Duration of Use : Many experts suggest starting with higher doses for 6-12 weeks before moving to a maintenance dose to replenish the body's levels effectively
Under moderate uracil misincorporation, BER efficiently repairs the damage
"It's more cost effective, and I think that's been the major barrier to getting people these medications, is cost and coverage," Egan said